Abstract 3245
Background
Chronic myeloid leukemia (CML) is a malignant clonal hematopoietic disorder characterized by a translocation between chromosomes 9 and 22 leading to the production of BCR-ABL fusion protein. This fusion produces mainly two variants, namely b3a2 and b2a2, rarely are other transcripts detected. To date, the exact role of these transcript variants are unknown and has shown mixed results. The objective of this study is to study the clinical-hematological profile and major molecular response rates (MMR) at 1 year in relation to b2a2 and b3a2 transcripts in CML-CP.
Methods
After approval from the institutional ethics committee, the data of patients attending medical oncology department from January 2014 to December 2015 (2 years) were collected and analyzed. A total of 154 patients were diagnosed with CML and 140 of them were in chronic phase (CP).
Results
Among 140 patients, males accounted for 88 (62%) and b3a2 type was seen in 99 patients (71%). Baseline parameters like hemoglobin, white cell count, platelet count, Sokal scoring, and EUTOS risk are shown in Table below. Follow up data was not available for 2 and 9 patients in b2a2 and b3a2 type, respectively.Table: 1099P
Parameter (N = 140) | B2a2 (n = 41) | B3a2 (n = 99) | P value |
---|---|---|---|
Mean Hemoglobin mg/dl SEM | 9.6 0.31 | 9.8 0.2 | 0.6 NS |
Mean Total Leucocyte Count (X109) SEM | 166 16.3 | 185 9.8 | 0.3 NS |
Mean Platelet Count (X109) SEM | 379 3.57 | 440 2.42 | 0.16 NS |
Sokal risk (%) Low Intermediate High | 3 (7) 20 (49) 18 (44) | 7 (7) 40 (40) 52 (53) | 0.63 NS |
EUTOS risk (%) Low High | 12 (30) 29 (70) | 53 (52) 47 (47) | 0.011 Significant |
MMR at 1 year (%) | 63 | 52 | 0.21 NS |
SEM: Standard Error of Mean After 1 year of therapy with Imatinib, 63% in b2a2 and 52% in b3a2 type achieved MMR (p-value 0.21). Twenty patients (14%) were evaluated for kinase domain resistance mutations (17 in b3a2 and 3 in b2a2). Seven out of 17 patients in b3a2 and none in b2a2 type had detectable mutations. Phase migration to accelerated or blast phase occurred in 3 (7%) and 9 (9%) in b2a2 and b3a2 transcript types respectively.
*SEM: Standard Error of Mean After 1 year of therapy with imatinib, 63% in b2a2 and 52% in b3a2 type achieved MMR (p-value 0.21). Twenty patients (14%) were evaluated for kinase domain resistance mutations (17 in b3a2 and 3 in b2a2). Seven out of 17 patients in b3a2 and none in b2a2 type had detectable mutations. Phase migration to accelerated or blast phase occurred in 3 (7%) and 9 (9%) in b2a2 and b3a2 transcript types, respectively.
Conclusions
There is no statistically significant difference between the two transcripts in relation to baseline hematological parameters. Patients with b2a2 type had higher EUTOS score at presentation. Despite this, at the end of 12 months, MMR rates were similar between b2a2 and b3a2 transcript types.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Siva K Prasad.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5553 - Cytokine genetic variations and worse quality of life among family caregivers of head and neck cancer patients in palliative care
Presenter: Daniel Pequeno
Session: Poster Display session 1
Resources:
Abstract
4321 - Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: a matched cohort study
Presenter: Annelies Boekhout
Session: Poster Display session 1
Resources:
Abstract
779 - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL
Presenter: Goutham Anugu
Session: Poster Display session 1
Resources:
Abstract
5914 - Cancer, Mental Health and End Life Simulation (CAMhELS): A novel effectiveness evaluation.
Presenter: Asanga Fernando
Session: Poster Display session 1
Resources:
Abstract
2597 - Cancer patients’ expectations and understanding about their disease
Presenter: Mónica Pinho
Session: Poster Display session 1
Resources:
Abstract
5187 - Impact of patients’ death on oncologists and coping strategies: An online survey
Presenter: Soumaya Labidi
Session: Poster Display session 1
Resources:
Abstract
4579 - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Presenter: Andrea Sbrana
Session: Poster Display session 1
Resources:
Abstract
5058 - Preparedness for caregiving in caregivers of cancer patients
Presenter: Hatice Yakar
Session: Poster Display session 1
Resources:
Abstract
5917 - Oncologic Emergency Medicine in the real world: A survey and proposal for improvement
Presenter: Carintia Dorta Pérez
Session: Poster Display session 1
Resources:
Abstract
4077 - The Reality of Critical Cancer Patients in a Polyvalent Intensive Care Unit
Presenter: Tiago Filipe Da Cruz Tomas
Session: Poster Display session 1
Resources:
Abstract